The CPX(TM) Control Breast Tissue Expanders can be utilized for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision and tissue defect procedures. The expander is intended for temporary subcutaneous or submuscular implantation and is not intended for use beyond six months.

Device Description

The CPX™ Control Breast Tissue Expander consists of a silicone elastomer shell, with interior structural elements to allow for directional expansion in the lower pole of the device. The device has an integral, silicone elastomer, magnetically detectable injection port. The injection port also incorporates a BUFFERZONE® area with self-sealing technology which is attached to the inside of the anterior surface of the device. The BUFFERZONE® is intended to minimize and/or prevent leakage in the event of an accidental needle puncture. Identification of the injection port site is accomplished by use of the CENTERSCOPE® Magnetic Injection Port Locator, which is provided with the Tissue Expander. When the Centerscope device is placed on top of the skin, the magnetic arm points to the center of the tissue expander's injection dome. Injections into the injection dome area are made using the provided infusion needle set to inject sterile, pyrogen-free Sodium Chloride U.S.P. Solution. The MENTOR CPX™ Control Breast Tissue Expander incorporates suture tabs to provide surgeons with the option to attach the device to surrounding tissue for enhanced device stability. The CPX Control devices are provided sterile in various styles and sizes. The following accessories are packaged with the CPX Control Tissue Expander: Centerscope Magnetic Injection Port Finder, Winged Infusion Set.

AI/ML Overview

This document describes a 510(k) premarket notification for the Mentor CPX™ Control Breast Tissue Expanders, submitted to the FDA. The purpose of the submission is to demonstrate substantial equivalence to a predicate device.

1. Table of acceptance criteria and the reported device performance:

Test Category	Acceptance Criteria (General)	Reported Device Performance
Biocompatibility	Materials should be biocompatible for permanent implant (> 30 days) as per ISO 10993-1.	All materials are identical to those used in the predicate device.
Mechanical Testing	Must meet pre-determined acceptance criteria for each test (e.g., Elongation, Tensile Strength, Break Force, Joint Testing, Overexpansion, Injection Valve Competency) as per Draft Guidance for Industry and Staff -Class II Special Controls Guidance for Tissue Expanders (December 22, 2008) and ASTM F1441-03.	All mechanical performance testing results met their pre-determined acceptance criteria.

2. Sample size used for the test set and the data provenance:

Sample Size: Not explicitly stated for each individual test. The document generally refers to "mechanical testing" being conducted.
Data Provenance: Not explicitly stated (e.g., country of origin). The testing was performed in support of the 510(k) submission, implying it's new data generated for the current device rather than retrospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

This information is not applicable to this submission. The "ground truth" here refers to the performance criteria established by recognized standards (ISO, ASTM) and FDA guidance for medical device testing, not expert consensus on medical images or diagnoses.

4. Adjudication method for the test set:

This information is not applicable. Adjudication methods are typically used in clinical studies or studies involving expert review of subjective data, not for objective mechanical and biocompatibility testing.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done:

No, an MRMC comparative effectiveness study was not conducted. This type of study is for evaluating diagnostic performance (e.g., of an AI algorithm) with human readers, which is not relevant for the mechanical and biocompatibility evaluation of a breast tissue expander.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

No, a standalone algorithm performance study was not conducted. This device is a physical medical device, not a software algorithm.

7. The type of ground truth used:

For biocompatibility: Adherence to recognized standards (ISO 10993-1) and the established biocompatibility of identical materials from the predicate device.
For mechanical testing: Adherence to recognized standards (ASTM F1441-03) and FDA guidance (Draft Guidance for Industry and Staff -Class II Special Controls Guidance for Tissue Expanders), which define the expected performance characteristics. The "ground truth" is that the device must perform within the specified parameters of these standards.

8. The sample size for the training set:

This information is not applicable. The device is a physical medical device, not a machine learning model, so there is no "training set."

9. How the ground truth for the training set was established:

This information is not applicable for the same reason as point 8.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized eagle or bird in flight, composed of three interconnected human profiles facing to the right.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 19, 2014

Mentor Worldwide LLC Ms. Manchi Cheung Regulatory Manager 201 Mentor Drive Santa Barbara, California 93111

Re: K142998

Trade/Device Name: CPX (TM) Control Breast Tissue Expanders Regulatory Class: Unclassified Product Code: LCJ Dated: October 16, 2014 Received: October 17, 2014

Dear Ms. Cheung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Binita S. Ashar -S

Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K142998

Device Name CPX (TM) Control Breast Tissue Expanders

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

_ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY

In accordance with 21 CFR 807.87(h) and (21 CFR 807.92) the 510(k) Summary for the Mentor CPX™ Control Breast Tissue Expanders is provided below.

I. SUBMITTER Mentor Worldwide LLC 201 Mentor Drive Santa Barbara, CA 93111

Contact Person: Manchi Cheung Regulatory Manager Phone: 805 -879-6790 Fax: 805-879-6167 mcheung3@its.jnj.com

Date Prepared: October 16, 2014

II. DEVICE

Name of Device:	Mentor CPX TM Control Breast Tissue Expanders
Common Device Name:	Expander, Skin, Inflatable
ClassificationRegulation:	Unclassified, Pre-Amendment
Panel:	General & Plastic Surgery
Product Code:	LCJ

III. PREDICATE DEVICE

K130813, Mentor CPX4 Breast Tissue Expanders and Mentor CPX 4 Breast Tissue Expanders with Suture Tabs This predicate has not been subjected to a design-related recall.

No reference devices were used in this submission.

IV. DEVICE DESCRIPTION

Identification of the injection port site is accomplished by use of the CENTERSCOPE®

{4}------------------------------------------------

Magnetic Injection Port Locator, which is provided with the Tissue Expander. When the Centerscope device is placed on top of the skin, the magnetic arm points to the center of the tissue expander's injection dome. Injections into the injection dome area are made using the provided infusion needle set to inject sterile, pyrogen-free Sodium Chloride U.S.P. Solution.

The MENTOR CPX™ Control Breast Tissue Expander incorporates suture tabs to provide surgeons with the option to attach the device to surrounding tissue for enhanced device stability.

The CPX Control devices are provided sterile in various styles and sizes.

The following accessories are packaged with the CPX Control Tissue Expander:

. Centerscope Magnetic Injection Port Finder
Winged Infusion Set ●

V. INDICATIONS FOR USE

The CPX™ Control Breast Tissue Expander can be utilized for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision and tissue defect procedures. The expander is intended for temporary subcutaneous or submuscular implantation and is not intended for use beyond six months.

VI. COMPARISON OF TECHOLOGICAL CHARACTERISTICS WITH PREDICATE

The technological principle for both the proposed and predicate devices is the same. Both devices expansion are based on incremental filling of a silicone shell with saline fluid to stretch the surrounding tissue. Filling is achieved via an integral injection dome with needle guard, and a magnetic injection finder to locate the dome.

The proposed and predicate devices are based on the following same technological elements:

Same intended use
Same operating principle ●
Same materials, same dimensional and volume ranges
Same integral injection Dome with neodymium needle guard
. Same BUFFERZONE® area with self-sealing technology around the injection dome to prevent accidental needle punctures
. Same suture tabs to attach device to surrounding tissue
Same use of reinforced silicone sheeting applied to areas of the device for directional expansion in the lower pole
. Compliance with the same recognized standards and test requirements.

The following additional design features are included in the proposed device. These design features are made using materials featured in the predicate device.

. An additional reinforced silicone sheeting is applied to the interior perimeter of the shell, adjacent to the base
. Use of tethering elements inside the shell to further minimize expansion in the upper pole and the area around the base, providing additional directional expansion to the lower pole.

{5}------------------------------------------------

VII. PERFORMANCE DATA

Biocompatibility Testing:

The CPX Control Breast Tissue Expander is an implantable device, the contact category according to ISO10993-1 is: Implant, tissue contacting, permanent (> 30 days). All materials used in the CPX Control tissue expander are identical to the materials used in the predicate device.

Mechanical Testing:

Mechanical testing was conducted in accordance with Draft Guidance for Industry and Staff -Class II Special Controls Guidance for Tissue Expanders, issued December 22, 2008 and ASTM F1441-03, Standard Specification for Soft-Tissue Expanders. The following mechanical testing was performed:

Elongation ●
. Tensile Strength
Break Force .
. Joint Testing
Overexpansion .
Injection Valve Competency ●

All mechanical performance testing results met their pre-determined acceptance criteria, thus demonstrating that the proposed device is substantially equivalent to the predicate device.

VIII. CONCLUSION

The CPX Control Breast Tissue Expander is substantially equivalent to the legally marketed predicate device, CPX4 Breast Tissue Expander and CPX4 Breast Tissue Expander with Suturing Tabs (K130813). The CPX Control Breast Tissue Expander has the same indications for use, operating principle and technological characteristics as the predicate device. Performance evaluations demonstrate that the subject device is substantially equivalent to the predicate device.

Regulation Number and Section

N/A